Catheter Precision (VTAK)
VIVO cardiac-mapping devices and FLYTE private aviation services.
Something off on this page? Send us feedback.
Generates product revenue from VIVO cardiac mapping systems and LockeT suture-retention devices, and service revenue from FLYTE’s charter and flight-coordination services, while the parent formally markets its medical business for sale.
Combines a cardiac-electrophysiology device business with FLYTE, a private-aviation platform, while management formally markets the medical operation for sale. The medical portfolio centers on VIVO, which maps the likely origin of ventricular arrhythmias before an electrophysiology procedure, and LockeT, a suture-retention device used after venous access.
FLYTE runs Flyte Hops short-haul charter flights and Flyte Luxe, which coordinates larger or longer-range trips with third-party aircraft and crews. It manages booking, scheduling, pricing, payment, fuel and flight planning, serving customers primarily in the northeastern and southeastern United States and selected other domestic markets.
Operations depend on hospital and physician adoption, medical regulatory clearances and reimbursement; aviation depends on operating authority, qualified pilots, fuel, insurance and third-party operators.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $3.3M · Total assets $36.9M · Shareholders' equity $17.6M
- Revenue
- $1.0M
- Operating income
- −$4.0M
- Net income
- −$3.9M
No dividends on record.
| Institutions12 holders · as of Mar 31, 2026 | 0.71% | 101.9K shares | |
| Strategic holders1 holder · as of Jul 20, 2026 | 7.40% | 1.07M shares | |
| Otherremainder | 91.89% | 13.22M shares |
14.39M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (14.39M in the company's Sep 3, 2026 report, 2.69M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Seg Jets SPV I, LLCStrategic | 7.40% | 1.07M | 13Gfiled Jul 20, 2026 ↗ |
C/M Capital Master Fund, LPInstitution | 6.10% | 878,451 | 13Gfiled Aug 21, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.33% | 47,659 | 13Fas of Mar 31, 2026 |
Virtu Financial LLCInstitution | 0.09% | 13,472 | 13Fas of Mar 31, 2026 |
Millennium Management LLCInstitution | 0.09% | 13,137 | 13Fas of Mar 31, 2026 |
| See all 18 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Wheels Up Experience
Leading private-aviation platform for U.S. charter demand.
- Abbott
Two-front rival in EP mapping and venous closure.
- flyExclusive
Direct charter and fleet-operator alternative.
- Johnson & Johnson
Large installed EP platform for mapping and ablation.
- Medtronic
Integrated EP mapping and ablation alternative.
- Boston Scientific
EP mapping and ablation platform with broad hospital reach.
- Haemonetics
Direct venous-closure alternative for EP procedures.
- Stryker
Direct suture-retention alternative after venous access.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Catheter Precision | $0.2001 | +0.91% | $540.4K | — | — | 0.3 | +380.7% |
| Wheels Up Experience | $4.32 | +0.23% | $156.6M | — | — | 0.2 | −4.0% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| flyExclusive | $1.18 | +2.62% | $93.6M | — | — | 0.2 | +21.7% |
| Johnson & Johnson | $275.21 | −0.01% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Medtronic | $92.18 | −0.02% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Boston Scientific | $48.45 | +0.16% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Haemonetics | $102.00 | −0.98% | $4.68B | 50.5 | 18.8 | 3.5 | +5.6% |
| Stryker | $315.43 | +1.04% | $119.68B | 32.4 | 19.4 | 4.6 | +9.4% |
| Median | 32.1 | 18.9 | 3.4 | +8.5% |